Tony Hodges, M.D., FACP, FCCP, - GuruFocus.com gurufocus.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gurufocus.com Daily Mail and Mail on Sunday newspapers.
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended De pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
PAION AG
PAION ANNOUNCES EXCLUSIVE LICENSING AGREEMENT WITH LA JOLLA PHARMACEUTICAL FOR GIAPREZA(TM) (ANGIOTENSIN II) AND XERAVA(TM) (ERAVACYCLINE) IN EUROPE
DGAP-News: PAION AG / Key word(s): Agreement
PAION ANNOUNCES EXCLUSIVE LICENSING AGREEMENT WITH LA JOLLA PHARMACEUTICAL FOR GIAPREZA(TM) (ANGIOTENSIN II) AND XERAVA(TM) (ERAVACYCLINE) IN EUROPE
12.01.2021 / 13:42
PAION ANNOUNCES EXCLUSIVE LICENSING AGREEMENT WITH
LA JOLLA PHARMACEUTICAL FOR GIAPREZA(TM) (ANGIOTENSIN II) AND XERAVA(TM) (ERAVACYCLINE) IN EUROPE
- PAION in-licenses exclusive rights to commercialize GIAPREZA(TM) and XERAVA(TM) throughout Europe
- La Jolla Pharmaceutical Company to receive USD 22.5 million upfront payment, up to USD 109.5 million in commercial milestone payments, and double-digit tiered royalty payments